Suchergebnisse - "2494G1JF75"

PubPharm (9)

1

Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells : beneficial effect of pravastatin

enthalten in: Antiviral therapy | 2014

von Auclair, M. | Afonso, P. | Capel, E. | +2

2

Post-exposure prophylaxis for HIV infection : a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine

enthalten in: Antiviral therapy | 2012

von Diaz-Brito, V. | León, A. | Knobel, H. | +9

3

Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes

enthalten in: Antiviral therapy | 2012

von Capel, E. | Auclair, M. | Caron-Debarle, M. | +1

4

In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients

enthalten in: Antiviral therapy | 2010

von Dierynck, I. | De Meyer, S. | Lathouwers, E. | +5

5

HIV protease inhibitors activate the adipocyte renin angiotensin system

enthalten in: Antiviral therapy | 2010

von Boccara, F. | Auclair, M. | Cohen, A. | +5

6

Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation

enthalten in: Antiviral therapy | 2008

von Boffito, M. | Else, L. | Back, D. | +6

7

Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients

enthalten in: Antiviral therapy | 2007

von Waters, L. | Moyle, G. | Bonora, S. | +8

8

Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir

enthalten in: Antiviral therapy | 2007

von Dam, E. | Lebel-Binay, S. | Rochas, S. | +7

9

Ritonavir-boosted atazanavir-lopinavir combination : a pharmacokinetic interaction study of total, unbound plasma and cellular exposures

enthalten in: Antiviral therapy | 2006

von Colombo, S. | Buclin, T. | Franc, C. | +8

1
[1]